PMID- 19342965
OWN - NLM
STAT- MEDLINE
DCOM- 20090619
LR  - 20211020
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 32
IP  - 4
DP  - 2009 May
TI  - Evaluation of 3 clinical dendritic cell maturation protocols containing 
      lipopolysaccharide and interferon-gamma.
PG  - 399-407
LID - 10.1097/CJI.0b013e31819e1773 [doi]
AB  - Dendritic cells (DCs) are important adjuvants for cancer vaccines. Immature 
      dendritic cells (iDCs) are often produced by the stimulation of peripheral blood 
      monocytes with interleukin (IL)-4 and granulocyte macrophage-colony stimulating 
      factor. For many applications iDCs are treated with cytokines or inflammatory 
      signals to produce mature DCs (mDCs). iDCs are often treated ex vivo with 
      lipopolysaccharide (LPS) and interferon (IFN)-gamma to produce mDCs for clinical 
      therapy. The purpose of this study was to determine if the DC maturation cocktail 
      LPS plus IFN-gamma could be improved by the addition of 2 other DC maturation 
      agents IL-1beta and tumor necrosis factor (TNF)-alpha. Peripheral blood 
      mononuclear cells were collected from 6 healthy subjects. Monocytes were isolated 
      from the peripheral blood mononuclear cell concentrates by elutriation and were 
      incubated for 3 days with granulocyte macrophage-colony stimulating factor and 
      IL-4 to produce iDCs. iDCs from each subject were divided into 3 and were 
      incubated for 24 hours with LPS plus IFN-gamma; LPS, IFN-gamma, plus IL-1beta; or 
      LPS, IFN-gamma, IL-1beta, plus TNF-alpha to produce mDCs. The DCs were compared 
      by measuring the expression of costimulator and antigen presenting molecules 
      (CD80, CD83, CD86, and human leukocyte antigen-DR) by flow cytometry, cytokine 
      production (IL-12p70 and IL-10) by enzyme-linked immunosorbent assay and global 
      gene expression using an oligonucleotide microarray. There were no differences in 
      the expression of costimulatory molecules, human leukocyte antigen-DR and CCR7 
      and production of IL-12p70 among the mDCs produced with the 3 cocktails. Global 
      gene expression analysis found that the expression of 9576 genes differed between 
      the iDCs and mDCs, but the expression of only 13 differed among the 3 different 
      groups of mDCs. There was no benefit of adding IL-1beta and TNF-alpha to LPS and 
      IFN-gamma to produce mDCs.
FAU - Han, Tae Hee
AU  - Han TH
AD  - Department of Transfusion Medicine, Clinical Center, National Institutes of 
      Health, 10 Center Drive, Bethesda, MD 20892, USA.
FAU - Jin, Ping
AU  - Jin P
FAU - Ren, Jiaqiang
AU  - Ren J
FAU - Slezak, Stefanie
AU  - Slezak S
FAU - Marincola, Francesco M
AU  - Marincola FM
FAU - Stroncek, David F
AU  - Stroncek DF
LA  - eng
GR  - Z01 CL002103-08/ImNIH/Intramural NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Interleukin-1beta)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - Cell Culture Techniques
MH  - Cell Differentiation
MH  - Dendritic Cells/*drug effects/*immunology
MH  - Gene Expression Profiling
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Interferon-gamma/*pharmacology
MH  - Interleukin-10/biosynthesis/immunology
MH  - Interleukin-12/biosynthesis/immunology
MH  - Interleukin-1beta/pharmacology
MH  - Interleukin-4/pharmacology
MH  - Lipopolysaccharides/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Oligonucleotide Array Sequence Analysis
MH  - Tumor Necrosis Factor-alpha/pharmacology
PMC - PMC2832587
MID - NIHMS126416
COIS- Financial Disclosure: The authors have declared there are no financial conflicts 
      of interests in regards to this article.
EDAT- 2009/04/04 09:00
MHDA- 2009/06/20 09:00
PMCR- 2010/05/01
CRDT- 2009/04/04 09:00
PHST- 2009/04/04 09:00 [entrez]
PHST- 2009/04/04 09:00 [pubmed]
PHST- 2009/06/20 09:00 [medline]
PHST- 2010/05/01 00:00 [pmc-release]
AID - 00002371-200905000-00009 [pii]
AID - 10.1097/CJI.0b013e31819e1773 [doi]
PST - ppublish
SO  - J Immunother. 2009 May;32(4):399-407. doi: 10.1097/CJI.0b013e31819e1773.